Abstract 2866
Background
In the Netherlands, hospice care is provided in professional-driven hospices and volunteer-driven hospices. To date, insight is lacking whether the care provided in hospices is appropriate to meet the patient’s needs and wishes. The aim is to gain insight into the characteristics of patients admitted in hospices, their needs and wishes and the care they receive.
Methods
A retrospective patient record study of 1200 hospice patients in the Netherlands. Preliminary results are shown for the first 203 patients. Inclusion criteria are deceased, adult patients admitted in hospice in 2017-2018.The following outcomes were included: Patient characteristics: demographics, disease characteristics, multidimensional symptoms, needs and wishes. Care characteristics: measurement instruments and multidimensional care. Descriptive statistisc was used for analyses.
Results
Preliminary results of 203 patients (mean age 74.8 years, 51.8% woman, 84% cancer diagnoses) from 13 hospices show that initiative for admission is mostly taken by the patient or their family (65.7%). Reasons for admission were described as physical symptoms (73.1%), preferred location of dying (16.1%) and social problems (9.7%). Patients were mostly admitted for last-resort (96.4%) and most patients were in the phase of symptom palliation (79.4%). Problems that were most described were delirium (18.6%), decubitus (12.4%) and edema (6.2%). On average, 10.6 interventions were performed in the first 72 hours per patient. Most were within the physical dimension (76.6%) and least in the social dimension (2.3%). Of the 11 different measurement tools identified, a symptom diary (20.7%) and a palliative assessment (17.2%) were most frequent used.
Conclusions
A preliminary overview of hospice patients and the care they receive was presented. The study is work in progress. Additional data and a comparison between organizational structures of hospices will be presented during the congress.
Clinical trial identification
Editorial acknowledgement
R. Koorn, F. van der Baan, E. de Graaf, S. Teunissen.
Legal entity responsible for the study
S.C.C.M. Teunissen.
Funding
ZonMw.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract